08:03 EDT Corvus Pharmaceuticals (CRVS) files automatic mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Corvus Pharmaceuticals: Strengthened Cash Runway and Expanding Soquelitinib Pipeline Underpin Buy Rating and Attractive Risk‑Reward Profile
- Corvus Pharmaceuticals reports Q4 EPS (15c), consensus (13c)
- Corvus Pharmaceuticals options imply 7.9% move in share price post-earnings
- Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market
- Corvus Advances Soquelitinib Into Phase 2 Eczema Trial: What Investors Should Watch